Compare LTC Properties Inc (LTC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Recursion Pharmaceuticals Inc — how do they compare? LTC Properties Inc trades at $42 (market cap $2.15B), while Recursion Pharmaceuticals Inc trades at $2.94 (market cap $1.53B). The key difference: LTC Properties Inc is the larger of the two by market cap, and LTC Properties Inc pays a 5.44% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LTC | RXRX | |
|---|---|---|
Market Cap | $2.15B | $1.53B |
Sector | Real Estate | Health |
52-Week High | $41.92 | $6.79 |
52-Week Low | $33.98 | $2.84 |
Enterprise Value | $2.99B | $946.50M |
Dividend Yield | 5.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $41.92, up 0.41% with a bullish technical outlook. The REIT shows strong fundamentals with 2025 revenue of $263M and net income of $118M, supported by a 67.3% gross margin. Recent acquisitions expand its SHOP portfolio, targeting demographic trends in senior housing. Analyst sentiment is mixed with 27% buy ratings amid recent earnings misses.
Outlook: Growth driven by strategic acquisitions and aging demographics, but execution risks and debt levels warrant caution. Near-term focus on Q2 2026 earnings (expected EPS $0.48) as a key catalyst. Dividend yield of ~5.4% provides income appeal.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
